Enrollment for BromSite Phase 3 Clinical Trial Begins by InSite Vision

InSite Vision Incorporated introduced that affected person enrollment has begun in the initial Phase 3 clinical trial of BromSite regarding the reduction of pain and inflammatory responses after cataract surgery. This research looks for to enroll about 240 affected individuals going through cataract operations within the two-arm trial devised to consider the efficacy and overall safety of BromSite contrary to the DuraSite vehicle alone. BromSite adds a low dose of the non-steroidal anti-inflammatory drug (NSAID) bromfenac along with InSite Vision's DuraSite drug delivery technique.

"BromSite has the possibility to substantially boost care for affected individuals undergoing cataract operations in the rapidly expanding eye surgery market," said Kamran Hosseini, M.D., Ph.D., Vice President and Chief Medical Officer of InSite Vision.

"We are actually confident this Phase 3 study would enroll rapidly offered the positive data aquired in our before clinical trials of BromSite, which includes statistically large reduction in pain and inflammation accomplished in our Phase 1/2 study in the same first endpoint as this trial. All of us look for top-line achievements out of this first Phase 3 survey will be featured in late 2012 or early 2013."